Global Coalition for Adaptive Research
The Global Coalition for Adaptive Research (GCAR) is a 501(c)(3) nonprofit organization dedicated to accelerating the discovery and development of treatments for patients with rare and deadly diseases through innovative clinical trials, including master protocols and adaptive platform trials.
Global Coalition for Adaptive Research
700 Larkspur Landing Circle, Suite 199, Larkspur, CA 94939-1754
What We Do
Clinical Trials
GCAR develops and sponsors innovative clinical trials to expedite the discovery of treatments for patients with rare and deadly diseases.
Research Collaboration
GCAR collaborates with various stakeholders including physicians, researchers, and pharmaceutical companies to enhance clinical trial designs.
Patient Advocacy
GCAR engages with patient advocacy groups to ensure that the needs and perspectives of patients are integrated into clinical research.
An adaptive global innovative learning environment for evaluating investigational therapies for patients with glioblastoma.
A sub-study of REMAP-CAP that tests multiple interventions for the treatment of patients hospitalized with COVID-19.
A protocol aimed at identifying safe and efficacious treatment options for newly diagnosed and recurrent ovarian cancer patients.
News & Updates
AstraZeneca’s AZD1390 to Join GBM AGILE, a Registrational-Intent Phase 2/3 Adaptive Platform Trial for Patients with Glioblastoma. Recruitment of patients expected to begin by Q2 2025.